BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sherbuk JE, Tabackman A, McManus KA, Kemp Knick T, Schexnayder J, Flickinger TE, Dillingham R. A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South. Harm Reduct J 2020;17:64. [PMID: 32948189 DOI: 10.1186/s12954-020-00409-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang AE, Hsieh E, Turner BJ, Terrault N. Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts. J Gen Intern Med 2022. [PMID: 35484367 DOI: 10.1007/s11606-022-07628-9] [Reference Citation Analysis]
2 Yazdani K, Dolguikh K, Zhang W, Shayegi-nik S, Ly J, Cooper S, Trigg J, Bartlett S, Barrios R, Montaner JSG, Salters K. Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy. PLoS ONE 2022;17:e0265811. [DOI: 10.1371/journal.pone.0265811] [Reference Citation Analysis]
3 Chan HK, Hassali MA, Mohammed NS, Azlan A, Hassan MRA. Barriers to scaling up hepatitis C treatment in Malaysia: a qualitative study with key stakeholders. BMC Public Health 2022;22:371. [PMID: 35189876 DOI: 10.1186/s12889-022-12786-w] [Reference Citation Analysis]
4 Marshall AD, Rance J, Grebely J, Treloar C. 'Not just one box that you tick off' - Deconstructing the hepatitis C care cascade in the interferon-free direct acting antiviral era from the client perspective. Int J Drug Policy 2022;102:103610. [PMID: 35151085 DOI: 10.1016/j.drugpo.2022.103610] [Reference Citation Analysis]
5 Kapadia SN, Johnson P, Marks KM, Schackman BR, Bao Y. Hepatitis C Treatment by Nonspecialist Providers in the Direct-acting Antiviral Era. Med Care 2021;59:795-800. [PMID: 34081676 DOI: 10.1097/MLR.0000000000001573] [Cited by in F6Publishing: 1] [Reference Citation Analysis]